



Cost and Efficiency Standing Committee Post-Comment Web Meeting

October 31, 2019

Welcome

NQF Staff

Project Staff

- Ashlie Wilbon, Senior Director
- Janaki Panchal, Project Manager
- Hannah Ingber, Project Analyst
- Taroon Amin, Consultant

Standing Committee

- Cheryl Damberg, PhD (co-chair)
- Kristine Martin Anderson, MBA
- Troy Fiesinger, MD, FAAFP
- Nancy Garrett, PhD
- Andrea Gelzer, MD, MS, FACP
- Rachael Howe, MS, BSN, RN
- Sunny Jhamnani, MD
- Lisa Latts, MD, MSPH, MBA, FACP
- Jason Lott, MD, MHS, MSHP, FAAP
- Jack Needleman, PhD
- Janis Orlowski, MD, MACP
- John Ratliff, MD, FACS, FAANS
- Srinivas Sridhara, PhD, MHS
- Lina Walker, PhD
- Bill Weintraub, MD, FACC
- Herbert Wong, PhD

Agenda



Review and Discuss Public Comments

Spring 2019 Committee Evaluation

Three new measures recommended for endorsement:

- **3509** Routine Cataract Removal with Intraocular Lens (IOL) Implantation (CMS/Acumen)
- **3510** Screening/Surveillance Colonoscopy (CMS/Acumen)
- **3512** Knee Arthroplasty (CMS/Acumen)

Commenting Summary

- Member/Public Comments
 - ▣ *6 total comments received*
 - » 4 comments on 3510 Screening/Surveillance Colonoscopy (CMS/Acumen)
 - » 2 comments on 3509 Routine Cataract Removal with Intraocular Lens (IOL) Implantation (CMS/Acumen)
 - *1 of these was considered during the evaluation webinars*
 - » Will review additional five today
- NQF received one member expression of support
 - ▣ *3510 Screening/Surveillance Colonoscopy*

Comment Themes

- **3509** Routine Cataract Removal with Intraocular Lens (IOL) Implantation (CMS/Acumen)
 - ▣ *Inclusion of certain drugs (pass through and post-operative)*
- **3510** Screening/Surveillance Colonoscopy (CMS/Acumen)
 - ▣ *Risk adjustment*
 - ▣ *Validity testing*
 - ▣ *Distinguishing performance*
- Action items:
 - ▣ *Review and discuss the comments and the developers' responses*
 - ▣ *Review and approve or revise the Committee response*
 - ▣ *Does the Committee wish to reconsider its evaluation ratings or endorsement recommendation?*

3509 Routine Cataract Removal with Intraocular Lens (IOL) Implantation

- A commenter raised concerns around the measure's inclusion of drugs with pass-through status because it may be a disincentive to surgeons using innovative treatments in cataract surgery.
- Further, the commenter disagrees with the inclusion of drugs used to treat post-operative conditions after cataract surgery since this treatment is not part of the cataract surgery itself.

(Refer to spreadsheet for detailed comments)

3509 Proposed Response

Thank you for your comment. While the Committee understands the commenters' concerns with the inclusion of pass through status and post-operative drugs in the measure, it also believes that episode-based cost measurement should include all relevant costs in the episode, including drugs used during the episode that are clinically related to the procedure and treatment of the condition during the episode. Therefore, excluding pass through or other drugs used during the episode of care, are appropriate for inclusion based on the definition of the episode and the intent of the measure.

- **Does the Committee agree with the proposed response?**
- **Does the Committee wish to reconsider its evaluation ratings or endorsement recommendation?**

3510 Screening/Surveillance Colonoscopy

- Commenters expressed concern regarding the limited testing results provided for the validity of the measure.
 - ▣ In particular commenters pointed to the analysis examining the correlation of the measure with relevant quality measures was not completed stating that instead, the developer ran correlations with other indicators of resource or service utilization.
 - ▣ Further, a commenter stated that the Committee's rationale for determining that the measure meet the validity criteria was unclear.
- Several commenters noted concerns around the risk adjustment for the measure. Commenters requested more information on the social risk factors that the developer used.
- One commenter stated that the testing does not directly address whether the costs attributed to physicians and practices distinguish “low” versus “high” performers.
- A commenter said that the measure was not intended to capture data specifically around bowel preparation as it relates to overutilization.

3510 Screening/Surveillance Colonoscopy

Validity Testing

- ▣ Seeking clarity on Committee response to the SMP's concern with validity testing approach
- ▣ Concerns with the low r-squared result for the risk adjustment model
- ▣ Concerns with the developer approach to risk adjustment and not including social risk factors; impact on performance and O/E ratio
- ▣ Concerns with whether the measure developer demonstrated meaningful differences in performance; implications for program design and benchmarking on distinguishing differences in performance on the measure
- ▣ Seeking clarification on the risk adjustment approach from developers

Intent of the Measure

- ▣ Concerns with the intent of the measure and its alignment with the measure and its design and future improvements as it relates to capturing bowel prep issues

3510 Comment Discussion

- Refer to the spreadsheet for discussion of each comment
- Committee discussion:
 - ▣ *Review and discuss the comments and the developers' responses*
 - ▣ *Determine committee response to commenters*
 - ▣ *Does the Committee wish to reconsider its evaluation ratings or endorsement recommendation for this measure?*

Public Comment

Next Steps

Committee Terms and Nominations

- Several Committee members with expiring terms
 - ▣ *Thank you!*
 - » Nancy Garrett
 - » Andrea Gelzer
 - » Lina Walker
 - » Bill Weintraub
 - » Herbert Wong
- Call for nominations in October to seat 14 new Committee members
 - ▣ *Nominations closed Oct 30*
 - ▣ *Thank you for your input!*

Upcoming Activities

- CSAC endorsement review of these measures:
November 12, 2019
- There were no measures submitted for the Fall 2019 cycle. There will be two web meetings:
 - ▣ *Orientation web meeting – **December 16, 2019, 2 pm - 4 pm ET***
 - » Orient new members
 - » Discuss measure pipeline/gap areas
 - » Path toward efficiency
 - ▣ *Strategic web meeting – **March 19, 2020, 1:30 pm - 3:30 pm ET***
 - » Combined call with the Readmissions Committee
 - » Discussion of social risk adjustment and the NQF trial results to-date for cost and readmissions measures

Project Contact Info

- Email: efficiency@qualityforum.org
- NQF phone: 202-783-1300
- Project page:
[https://www.qualityforum.org/Cost and Efficiency.aspx](https://www.qualityforum.org/Cost_and_Efficiency.aspx)
- SharePoint site:
<http://share.qualityforum.org/Projects/costEff/SitePages/Home.aspx>

Adjourn